Opinion|Videos|October 23, 2024
Unmet Needs and Future Research
Key Takeaways
- Understanding disease pathophysiology is essential for developing personalized treatment strategies and improving patient outcomes in type 2 inflammatory diseases.
- Identifying biomarkers can enhance disease monitoring and predict treatment responses, facilitating more effective management.
Panelists discuss how unmet needs in type 2 inflammatory diseases require further research, including developing more personalized treatment approaches, identifying novel biomarkers for better disease phenotyping, improving long-term disease control strategies, and addressing the psychosocial impacts of chronic inflammatory conditions to enhance patients’ overall quality of life and outcomes.
Advertisement
Episodes in this series
- What unmet needs require further research to improve quality of life and outcomes for patients living with type 2 inflammatory diseases?
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
3
Disability, Economic Toll of Multimorbidity Climb in Older Adults
4
October FDA Approvals Bring Advances Across 5 Specialties
5